{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:58:41Z","timestamp":1790834321543,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bulcan.2021.04.008","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T09:21:31Z","timestamp":1625822491000},"page":"S53-S64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S","title":["Suivi immunologique des patients trait\u00e9s par cellules CAR-T pour h\u00e9mopathie maligne: recommandations du groupe CARTi et de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"108","author":[{"given":"Marie Th\u00e9r\u00e8se","family":"Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Allain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ballot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Cuffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Foguenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Guihot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Latouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Lemarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martinroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Simonetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Caillat Zucman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0285","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2021.04.008_bib0290","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","article-title":"Biomarkers in individualized management of chimeric antigen receptor T cell therapy","volume":"8","author":"Du","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0300","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on beh**alf of the chronic malignancies working party of EBMT","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.04.008_bib0305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2\u00a0trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0320","first-page":"17","article-title":"Treatment with anti CD19\u00a0chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"22","key":"10.1016\/j.bulcan.2021.04.008_bib0325","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.bulcan.2021.04.008_bib0330","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0335","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2021.04.008_bib0340","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T-Cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.04.008_bib0345","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19\u00a0chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.bulcan.2021.04.008_bib0350","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121\u00a0in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.04.008_bib0355","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bulcan.2021.04.008_bib0360","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.bulcan.2021.04.008_bib0365","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19\u00a0CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.bulcan.2021.04.008_bib0370","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2021.04.008_bib0375","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19\u00a0CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2021.04.008_bib0380","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19\u00a0chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bulcan.2021.04.008_bib0385","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19\u00a0chimeric antigen receptor T Cells are associated with high serum interleukin-15\u00a0Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2021.04.008_bib0390","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19\u00a0CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2021.04.008_bib0395","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19\u00a0CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0400","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3389\/fimmu.2020.01985","article-title":"Chimeric antigen receptor T Cell therapy for pediatric B-ALL: narrowing the gap between early and long-term outcomes","volume":"11","author":"Schultz","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.04.008_bib0405","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0410","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-0146-4_17","article-title":"Analysis of CAR-mediated tonic signaling","volume":"2086","author":"Calderon","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.04.008_bib0415","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"544","key":"10.1016\/j.bulcan.2021.04.008_bib0420","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"issue":"26","key":"10.1016\/j.bulcan.2021.04.008_bib0425","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bulcan.2021.04.008_bib0430","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019\u00a0in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2021.04.008_bib0435","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19\u00a0CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"1S","key":"10.1016\/j.bulcan.2021.04.008_bib0440","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.bulcan.2018.12.001","article-title":"Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)","volume":"106","author":"Yakoub-Agha","year":"2019","journal-title":"Bull Cancer"},{"issue":"21","key":"10.1016\/j.bulcan.2021.04.008_bib0445","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19\u00a0chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0450","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0455","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.bulcan.2021.04.008_bib0460","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0465","article-title":"Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)","author":"Cornillon","year":"2019","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2021.04.008_bib0470","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.bulcan.2021.04.008_bib0475","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19\u00a0CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19\u00a0as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0485","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","author":"Logue","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0490","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2021.04.008_bib0495","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.bulcan.2021.04.008_bib0500","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2021.04.008_bib0505","doi-asserted-by":"crossref","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bulcan.2021.04.008_bib0510","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0515","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2020.01770","article-title":"The chimeric antigen receptor detection toolkit","volume":"11","author":"Hu","year":"2020","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.bulcan.2021.04.008_bib0520","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0525","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fmolb.2020.00084","article-title":"Digital-droplet PCR for quantification of CD19-directed CAR T-Cells","volume":"7","author":"Mika","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.008_bib0530","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.transproceed.2017.11.028","article-title":"Establishment of a quantitative polymerase chain reaction assay for monitoring chimeric antigen receptor T Cells in peripheral blood","volume":"50","author":"Wang","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bulcan.2021.04.008_bib0535","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"10.1016\/j.bulcan.2021.04.008_bib0540","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/hgtb.2016.059","article-title":"Application of droplet digital PCR for estimating vector copy number states in stem cell gene therapy","volume":"27","author":"Lin","year":"2016","journal-title":"Hum Gene Ther Methods"},{"issue":"11","key":"10.1016\/j.bulcan.2021.04.008_bib0545","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1006\/cyto.2000.0764","article-title":"Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin","volume":"12","author":"Flower","year":"2000","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.bulcan.2021.04.008_bib0550","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/aji.12512","article-title":"Simple plex: a novel multi-analyte, automated microfluidic immunoassay platform for the detection of human and mouse cytokines and chemokines","volume":"75","author":"Aldo","year":"2016","journal-title":"Am J Reprod Immunol"},{"issue":"11S","key":"10.1016\/j.bulcan.2021.04.008_bib0555","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"12S","key":"10.1016\/j.bulcan.2021.04.008_bib0280","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.bulcan.2017.10.017","article-title":"Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"104","author":"Yakoub-Agha","year":"2017","journal-title":"Bull Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:24Z","timestamp":1762104024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0007455121002058"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.04.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suivi immunologique des patients trait\u00e9s par cellules CAR-T pour h\u00e9mopathie maligne: recommandations du groupe CARTi et de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}